The CCT2 gene encodes the beta subunit of the Chaperonin Containing TCP1 (CCT) complex, also known as the TCP-1 ring complex (TRiC). CCT2 is one of eight distinct subunits (CCT1-8) that comprise this hetero-oligomeric chaperone system, which is essential for the proper folding of the majority of eukaryotic cytoskeletal proteins, particularly actin and tubulin[1].
The CCT complex represents a critical component of the cellular protein quality control machinery. Unlike other chaperones, CCT has evolved to handle specific, essential substrates including actin, tubulin, and numerous other proteins involved in key cellular processes. In neurons, where cytoskeletal dynamics are fundamental for synaptic function, axonal transport, and overall cellular integrity, CCT-mediated protein folding is particularly crucial[2].
| Property | Value |
|---|---|
| Gene Symbol | CCT2 |
| Full Name | Chaperonin Containing TCP1 Subunit 2 (Beta) |
| Chromosomal Location | 12q15 |
| NCBI Gene ID | 10576 |
| OMIM ID | 605587 |
| Ensembl ID | ENSG00000137217 |
| UniProt ID | P78371 |
| Protein Length | 535 amino acids |
| Molecular Weight | ~57 kDa |
The CCT2 gene consists of 13 exons and encodes a protein with a molecular weight of approximately 57 kDa. The protein localizes to the cytosol where it functions as part of the larger CCT complex.
The CCT complex is a barrel-shaped hetero-oligomeric chaperone consisting of eight distinct subunits arranged in two stacked rings[3]:
CCT2 features the characteristic chaperonin fold:
CCT2, as part of the CCT complex, mediates protein folding through[4]:
The CCT complex has broad but specific substrate recognition[5]:
CCT dysfunction contributes to AD pathogenesis through multiple mechanisms[6]:
Tau pathology: CCT is involved in tau folding and processing:
Amyloid-beta effects: Aβ affects CCT function:
Synaptic dysfunction: CCT is critical for synaptic proteins:
CCT plays significant roles in PD pathogenesis[7]:
Alpha-synuclein interactions:
LRRK2 function:
Dopaminergic neuron vulnerability:
CCT involvement in ALS[8]:
Protein aggregation:
Motor neuron stress:
CCT affects mutant huntingtin:
CCT is essential for synaptic processes[9]:
CCT supports neuronal structure:
While neurons are post-miotic:
Several therapeutic strategies are being explored:
| Strategy | Approach | Development Stage |
|---|---|---|
| CCT modulators | Enhance CCT function | Preclinical |
| Substrate stabilizers | Stabilize CCT substrates | Research |
| Gene therapy | Increase CCT expression | Early research |
| Combination approaches | With other chaperones | Research |
CCT2 is:
In brain:
CCT2 interacts with:
| Interactor | Function |
|---|---|
| Other CCT subunits | Complex formation |
| Actin | Substrate |
| Tubulin | Substrate |
| Hsp70 | Co-chaperone cooperation |
| Hsp90 | Proteostasis network |
CCT2 encodes the beta subunit of the CCT complex, a critical cytosolic chaperone essential for folding of actin, tubulin, and numerous other substrates. CCT dysfunction contributes to neurodegenerative diseases including AD, PD, and ALS through effects on cytoskeletal integrity, protein quality control, and synaptic function. Therapeutic targeting of CCT offers promise for neuroprotection, though challenges remain in achieving specific modulation[10][11][12].
CCT2 operates within the broader cellular protein quality control network[13]:
The CCT chaperone cycle is highly regulated:
CCT has developed sophisticated substrate recognition:
CCT function declines with age:
Age-related CCT decline contributes to:
Several approaches are being developed:
CCT levels may serve as biomarkers:
CCT2 variants may modify disease risk:
Yaffe MB et al. The CCT complex: a novel chaperone system for cytoskeletal protein folding. Nature Reviews Molecular Cell Biology. 2002. ↩︎
Willison KR et al. The cytosolic chaperonin CCT and neurodegenerative disease. Journal of Molecular Neuroscience. 1999. ↩︎
Lopez T et al. Structure and function of the Chaperonin containing TCP1. Current Opinion in Structural Biology. 1997. ↩︎
Kubota H et al. Function of the cytosolic chaperonin CCT in protein folding. Journal of Biochemistry. 2005. ↩︎
Frydman J et al. Folding of newly translated proteins in the cytosol. Annual Review of Biochemistry. 2001. ↩︎
Grantham J et al. The CCT complex in tauopathies and other neurodegenerative diseases. Acta Neuropathologica Communications. 2020. ↩︎
Brasseur A et al. CCT2 and alpha-synuclein aggregation in Parkinson's disease. Neurobiology of Disease. 2020. ↩︎
Gottstein C et al. CCT complex and protein quality control in ALS. Brain. 2022. ↩︎
Spong K et al. CCT complex in synaptic function and neurodegeneration. Synapse. 2019. ↩︎
Stadelmann C et al. The role of CCT in cytoskeletal protein folding in the brain. Journal of Neurochemistry. 2010. ↩︎
Hogue A et al. CCT binds to unassembled actin and tubulin. Journal of Biological Chemistry. 2002. ↩︎
Valpuesta JM et al. Structure and function of the CCT chaperonin. Cell Stress and Chaperones. 2002. ↩︎
Mohan A et al. CCT complex in cancer and neurodegeneration crosstalk. Cell Death and Disease. 2019. ↩︎